http://jnci.oxfordjournals.org/content/105/9/595.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/105/9/595" />
      <meta content="/jnci/105/9/595.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis"
            name="DC.Title" />
      <meta content="10.1093/jnci/djt072" name="DC.Identifier" />
      <meta content="2013-05-01" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Chee Khoon Lee" name="DC.Contributor" />
      <meta content="Chris Brown" name="DC.Contributor" />
      <meta content="Richard J. Gralla" name="DC.Contributor" />
      <meta content="Vera Hirsh" name="DC.Contributor" />
      <meta content="Sumitra Thongprasert" name="DC.Contributor" />
      <meta content="Chun-Ming Tsai" name="DC.Contributor" />
      <meta content="Eng Huat Tan" name="DC.Contributor" />
      <meta content="James Chung-Man Ho" name="DC.Contributor" />
      <meta content="Da Tong Chu" name="DC.Contributor" />
      <meta content="Adel Zaatar" name="DC.Contributor" />
      <meta content="Jemela Anne Osorio Sanchez" name="DC.Contributor" />
      <meta content="Vu Van Vu" name="DC.Contributor" />
      <meta content="Joseph Siu Kie Au" name="DC.Contributor" />
      <meta content="Akira Inoue" name="DC.Contributor" />
      <meta content="Siow Ming Lee" name="DC.Contributor" />
      <meta content="Val Gebski" name="DC.Contributor" />
      <meta content="James Chih-Hsin Yang" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Chee Khoon Lee" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Chris Brown" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Richard J. Gralla" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Vera Hirsh" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Sumitra Thongprasert" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Chun-Ming Tsai" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Eng Huat Tan" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="James Chung-Man Ho" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Da Tong Chu" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Adel Zaatar" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Jemela Anne Osorio Sanchez" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Vu Van Vu" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Joseph Siu Kie Au" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Akira Inoue" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Siow Ming Lee" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="Val Gebski" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta name="citation_author" content="James Chih-Hsin Yang" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors: National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill University Health Center, Royal Victoria Hospital, Montreal, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University of Hong Kong, Hong Kong, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (DTC); Gleneagles Hospital, Penang, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, Cebu City, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, Sendai, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan (JC-HY)." />
      <meta content="Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis"
            name="citation_title" />
      <meta content="05/01/2013" name="citation_date" />
      <meta content="105" name="citation_volume" />
      <meta content="9" name="citation_issue" />
      <meta content="595" name="citation_firstpage" />
      <meta content="605" name="citation_lastpage" />
      <meta content="105/9/595" name="citation_id" />
      <meta content="105/9/595" name="citation_id_from_sass_path" />
      <meta content="jnci;105/9/595" name="citation_mjid" />
      <meta content="10.1093/jnci/djt072" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/105/9/595.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/105/9/595.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/105/9/595.full.pdf"
            name="citation_pdf_url" />
      <meta content="/content/105/9.cover.gif" name="issue_cover_image" />
      <meta content="http://jnci.oxfordjournals.org/content/105/9/595"
            name="citation_public_url" />
      <meta content="23594426" name="citation_pmid" />
      <meta name="citation_section" content="Review" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/105/9/593.short" rel="prev" />
      <link href="/content/105/9/606.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d28392962e1">var callbackToken='5370D5F53412B43';</script><script type="text/javascript" id="session-d28392962e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:13:51.824-07:00';
            var gSessionId = 'wtH8-CreQnl8Y7xz9UmXnw';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djt072");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20130501");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F105%2F9%2F595.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/105/9.toc">
                  <span xmlns="" class="volume-value">Volume 105</span>
                  <span xmlns="" class="issue-value"> Issue 9</span></a></li>
            <li>Pp. <span class="slug-pages">
                  595-605.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/105/9/595.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view " itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Chee+Khoon+Lee&amp;sortspec=date&amp;submit=Submit">Chee Khoon Lee</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Chris+Brown&amp;sortspec=date&amp;submit=Submit">Chris Brown</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Richard+J.+Gralla&amp;sortspec=date&amp;submit=Submit">Richard J. Gralla</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Vera+Hirsh&amp;sortspec=date&amp;submit=Submit">Vera Hirsh</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Sumitra+Thongprasert&amp;sortspec=date&amp;submit=Submit">Sumitra Thongprasert</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Chun-Ming+Tsai&amp;sortspec=date&amp;submit=Submit">Chun-Ming Tsai</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-7" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Eng+Huat+Tan&amp;sortspec=date&amp;submit=Submit">Eng Huat Tan</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-8" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=James+Chung-Man+Ho&amp;sortspec=date&amp;submit=Submit">James Chung-Man Ho</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-9" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Da+Tong+Chu&amp;sortspec=date&amp;submit=Submit">Da Tong Chu</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-10" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Adel+Zaatar&amp;sortspec=date&amp;submit=Submit">Adel Zaatar</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-11" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Jemela+Anne+Osorio+Sanchez&amp;sortspec=date&amp;submit=Submit">Jemela Anne Osorio Sanchez</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-12" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Vu+Van+Vu&amp;sortspec=date&amp;submit=Submit">Vu Van Vu</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-13" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Joseph+Siu+Kie+Au&amp;sortspec=date&amp;submit=Submit">Joseph Siu Kie Au</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-14" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Akira+Inoue&amp;sortspec=date&amp;submit=Submit">Akira Inoue</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-15" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Siow+Ming+Lee&amp;sortspec=date&amp;submit=Submit">Siow Ming Lee</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-16" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Val+Gebski&amp;sortspec=date&amp;submit=Submit">Val Gebski</a></span> and 
                     </li>
                     <li class="last" id="contrib-17"><span class="name"><a class="name-search"
                              href="/search?author1=James+Chih-Hsin+Yang&amp;sortspec=date&amp;submit=Submit">James Chih-Hsin Yang</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address>
                           <strong>Affiliations of authors:</strong> National Health and Medical Research Council Clinical Trials Centre, University of Sydney, <span class="addr-line">Sydney</span>, Australia (CKL, CB, VG); Albert Einstein College of Medicine, Jacobi Medical Center, South Bronx, New York (RJG); McGill
                           University Health Center, Royal Victoria Hospital, <span class="addr-line">Montreal</span>, Canada (VH); Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, <span class="addr-line">Chiang Mai</span>, Thailand (ST); Department of Chest Medicine, Taipei Veterans General Hospital, <span class="addr-line">Taipei</span>, Taiwan (C-MT); Department of Medical Oncology, National Cancer Center, Singapore (EHT); Department of Medicine, University
                           of Hong Kong, <span class="addr-line">Hong Kong</span>, China (JC-MH); Cancer Hospital, Chinese Academy of Medical Sciences, <span class="addr-line">Beijing</span>, China (DTC); Gleneagles Hospital, <span class="addr-line">Penang</span>, Malaysia (AZ); St Paul of Chartes, Medical Specialty Center, Perpetual Succor Hospital, <span class="addr-line">Cebu City</span>, Philippines (JAOS); Ho Chi Minh City’s Oncology Hospital, Ho Chi Minh City, Vietnam (VVV); Department of Clinical Oncology,
                           Queen Elizabeth Hospital, <span class="addr-line">Hong Kong</span>, China (JSKA); Department of Respiratory Medicine, Tohoku University Hospital 1-1, <span class="addr-line">Sendai</span>, Japan (AI); Department of Oncology, University College London (UCL) Cancer Institute and UCL Hospitals, <span class="addr-line">London</span>, United Kingdom (SML); Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College of Medicine,
                           <span class="addr-line">Taipei</span>, Taiwan (JC-HY).
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="corresp" id="corresp-1">
                        <strong>Correspondence to:</strong><br /> James Chih-Hsin Yang, MD, PhD, Graduate Institute of Oncology and Cancer Research Center, National Taiwan University College
                        of Medicine, Taipei 10051, Taiwan (e-mail: <span class="em-link"><span class="em-addr">chihyang{at}ntu.edu.tw</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2012-08-17"><span class="received-label">Received </span>August 17, 2012.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2013-01-05"><span class="rev-recd-label">Revision received </span>January 5, 2013.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2013-02-15"><span class="accepted-label">Accepted </span>February 15, 2013.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-5" title="Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  
                  <div id="sec-1" class="subsection">
                     
                     
                     <p id="p-1"><strong>Background</strong> The epidermal growth factor receptor (EGFR) signaling pathway is crucial for regulating tumorigenesis and cell survival and
                        may be important in the development and progression of non–small cell lung cancer (NSCLC). We examined the impact of EGFR–tyrosine
                        kinase inhibitors (TKIs) on progression-free survival (PFS) and overall survival (OS) in advanced NSCLC patients with and
                        without EGFR mutations.
                     </p>
                     
                  </div>
                  
                  <div id="sec-2" class="subsection methods">
                     
                     
                     <p id="p-2"><strong>Methods</strong> Randomized trials that compared EGFR-TKIs monotherapy or combination EGFR-TKIs-chemotherapy with chemotherapy or placebo
                        were included. We used published hazard ratios (HRs), if available, or derived treatment estimates from other survival data.
                        Pooled estimates of treatment efficacy of EGFR-TKIs for the EGFR mutation–positive (EGFRmut<sup>+</sup>) and EGFR mutation–negative (EGFRmut<sup>–</sup>) subgroups were calculated with the fixed-effects inverse variance weighted method. All statistical tests were two-sided.
                     </p>
                     
                  </div>
                  
                  <div id="sec-3" class="subsection">
                     
                     
                     <p id="p-3"><strong>Results</strong> We included 23 eligible trials (13 front-line, 7 second-line, 3 maintenance; n = 14570). EGFR mutation status was known in
                        31% of patients. EGFR-TKIs treatment prolonged PFS in EGFRmut<sup>+</sup> patients, and EGFR mutation was predictive of PFS in all settings: The front-line hazard ratio for EGFRmut<sup>+</sup> was 0.43 (95% confidence interval [CI] = 0.38 to 0.49; <em>P</em> &lt; .001), and the front-line hazard ratio for EGFRmut<sup>–</sup> was 1.06 (95% CI = 0.94 to 1.19; <em>P</em> = .35; <em>P</em>
                        <sub>interaction</sub> &lt; .001). The second-line hazard ratio for EGFRmut<sup>+</sup> was 0.34 (95% CI = 0.20 to 0.60; <em>P</em> &lt; .001), and the second-line hazard ratio for EGFRmut<sup>–</sup> was 1.23 (95% CI = 1.05 to 1.46; <em>P</em> = .01; <em>P</em>
                        <sub>interaction</sub> &lt; .001). The maintenance hazard ratio for EGFRmut<sup>+</sup> was 0.15 (95% CI = 0.08 to 0.27; <em>P</em> &lt; .001), and the maintenance hazard ratio for EGFRmut<sup>–</sup> was 0.81 (95% CI = 0.68 to 0.97; <em>P</em> = .02; <em>P</em>
                        <sub>interaction</sub> &lt; .001). EGFR-TKIs treatment had no impact on OS for EGFRmut<sup>+</sup> and EGFRmut<sup>–</sup> patients.
                     </p>
                     
                  </div>
                  
                  <div id="sec-4" class="subsection">
                     
                     
                     <p id="p-4"><strong>Conclusions</strong> EGFR-TKIs therapy statistically significantly delays disease progression in EGFRmut<sup>+</sup> patients but has no demonstrable impact on OS. EGFR mutation is a predictive biomarker of PFS benefit with EGFR-TKIs treatment
                        in all settings. These findings support EGFR mutation assessment before initiation of treatment. EGFR-TKIs should be considered
                        as front-line therapy in EGFRmut<sup>+</sup> advanced NSCLC patients.
                     </p>
                     
                  </div>
                  
               </div>
               <p id="p-5">The greatest changes in the treatment of advanced non–small cell lung cancer (NSCLC) have been novel molecular-targeted agents
                  and the concomitant ability to personalize treatment. Controversy continues in many areas related to the incorporation of
                  these changes into clinical medicine. How should such therapy be selected for individual patients? Is molecular testing required
                  or is the use of demographic factors (such as histologic NSCLC type, sex, smoking history) sufficient for personalizing therapy?
                  Questions remain concerning whether therapy with chemotherapy or with agents affecting the epidermal growth factor receptor
                  (EGFR) influence progression-free survival (PFS) and/or overall survival (OS) in patients who do or do not harbor known mutations
                  associated with EGFR. Is PFS a good surrogate for OS, or is PFS a useful endpoint on its own? Data directed at answering these
                  controversies can guide oncologists in interpreting trials and in making more appropriate diagnostic and therapeutic choices
                  for hundreds of thousands of patients each year.
               </p>
               <p id="p-6" class="indent">The objective of this meta-analysis is to estimate better the treatment effect of EGFR–tyrosine kinase inhibitors (TKIs) on
                  PFS and OS while examining for heterogeneity of treatment effects between groups of patients with and without EGFR mutations.
                  The EGFR signaling pathway is crucial for regulating tumorigenesis and cell survival and may be overexpressed in the development
                  and progression of NSCLC (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1–3</a>). Patients with activating somatic mutations in the region of the EGFR gene that encodes the tyrosine kinase domain are highly
                  responsive to EGFR-TKIs (<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4–6</a>). Previously published meta-analyses have been limited by studying the minority of patients with NSCLC—that is, the influence
                  of EGFR-TKIs only in the population of patients harboring EGFR mutations and predominantly in the front-line treatment setting
                  (<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7–9</a>). These meta-analyses have not demonstrated an OS advantage for patients with EGFR mutation treated with EGFR-TKIs. This
                  analysis uses all trial data available to date and examines the effect of EGFR-TKIs treatment in major clinical settings—front-line,
                  maintenance, and second-line or subsequent therapies. Additionally, the impact of EGFR-TKIs-chemotherapy combinations compared
                  with EGFR-TKIs monotherapy is also explored. It is now recognized that as with EGFR mutations, other genetic alterations [such
                  as EML-ALK abnormalities (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>) and ROS-1 mutations (<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>)] are also more common in nonsmokers with adenocarcinoma, but these latter groups do not benefit from EGFR-TKIs–directed
                  therapy. Such findings highlight the need for more specific molecular testing of patients and the need to include the most
                  recent data from meta-analyses to understand better the treatment effects.
               </p>
               <p id="p-7" class="indent">Individual trials and meta-analyses have clearly indicated that PFS and response rates are improved in patients with EGFR
                  mutation who are treated with EGFR-TKIs, when compared with chemotherapy (<a id="xref-ref-7-2" class="xref-bibr" href="#ref-7">7–9</a>). The impact on OS is less clear, especially in patients treated beyond first-line therapy. Two separate trials have indicated
                  that erlotinib is effective as second-line (<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>) and maintenance (<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>) therapy, with no statistically significant difference in treatment effect between those with EGFR mutation and wild-type
                  tumors. However, a recent trial reported that chemotherapy was superior over erlotinib as second-line treatment for patients
                  without EGFR mutations in exon 19 or 21 (<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>). Clearly, newer and larger meta-analyses are required to resolve these differences. Definitive analyses can provide stronger
                  rationales for the choice of a specific therapy and can result in better utilization of health-care resources with these costly
                  agents. For these reasons, we conducted this meta-analysis, which included the largest number of studies and patients to date
                  with known EGFR mutation status and tested both PFS and OS as outcomes.
               </p>
               <div class="section methods" id="sec-5">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-9" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Methods</h2>
                  
                  <div id="sec-6" class="subsection">
                     
                     <h3>Study Eligibility and Identification</h3>
                     
                     <p id="p-8">All randomized trials of EGFR-TKIs monotherapy vs any chemotherapy, EGFR-TKIs and chemotherapy vs the same chemotherapy alone,
                        and EGFR-TKIs monotherapy vs placebo or best supportive care were eligible for inclusion.
                     </p>
                     
                     <p id="p-9" class="indent">Trials were identified from previous meta-analyses (<a id="xref-ref-7-3" class="xref-bibr" href="#ref-7">7–9</a>), and a search of Medline, Embase, CancerLit, and the Cochrane Central Register of Controlled Trials (CENTRAL) using the
                        following terms: lung neoplasms, non–small cell lung cancer, gefitinib, erlotinib, EGFR, meta-analysis, systemic review, randomized,
                        and clinical trials. Database searches were restricted to articles published in the English language between January 1, 2004,
                        and June 6, 2012. Trials that enrolled patients with prior EGFR-TKIs treatment were excluded. Abstracts from conference proceedings
                        of the American Society of Clinical Oncology, the European Society for Medical Oncology, and the World Lung Cancer Conference
                        were searched to identify unpublished studies. Individual study sponsors (Hoffmann-La Roche and AstraZeneca) were contacted
                        for relevant presentation slides and posters from these conferences when they were inaccessible from the websites. Individual
                        investigators were also contacted if essential information relevant to this meta-analysis was unavailable from these sources.
                     </p>
                     
                  </div>
                  
                  <div id="sec-7" class="subsection">
                     
                     <h3>Data Extraction</h3>
                     
                     <p id="p-10">Information recorded from each trial included study name, year of publication or conference presentation, study design, line
                        of treatment, and clinicopathological and demographic data. Mutational analysis data were also extracted, and the different
                        methods of EGFR mutation assessment were recorded. We classified patients as EGFR mutation–positive (EGFRmut<sup>+</sup>) based on the presence of a mutation as detected using molecular assessment tools such as Sanger sequencing, polymerase chain
                        reaction clamp, and amplification refractory mutation system. Patients were classified as EGFR mutation–negative (EGFRmut<sup>–</sup>) if no mutation was detected. We did not classify patients’ EGFR mutation status based on immunohistochemistry and fluorescent
                        in situ hybridization for EGFR gene copy numbers. Most trials analyzed exons 19 and 21 for EGFR mutations, and some trials
                        also included exons 18 and 20.
                     </p>
                     
                     <p id="p-11" class="indent">Data were extracted independently by three authors (J. C.-H. Yang, C. K. Lee, and C. Brown), and discrepancies were resolved
                        by consensus including a fourth author (V. Gebski).
                     </p>
                     
                  </div>
                  
                  <div id="sec-8" class="subsection">
                     
                     <h3>Statistical Analyses</h3>
                     
                     <p id="p-12">We extracted the hazard ratios (HRs) and the associated 95% confidence intervals (CIs) for PFS and OS outcomes to assess treatment
                        efficacy within the EGFRmut<sup>+</sup> and EGFRmut<sup>–</sup> subgroups. Where available, we included the most updated OS data. If hazard ratios and confidence intervals were not reported,
                        these were estimated where possible using the methods of Parmar (<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>).
                     </p>
                     
                     <p id="p-13" class="indent">Pooled estimates of the treatment efficacy of EGFR-TKIs for the EGFRmut<sup>+</sup> and EGFRmut<sup>–</sup> subgroups were calculated by using the fixed-effects inverse variance weighted method. We performed indirect comparisons
                        to quantify the benefits of adding chemotherapy to EGFR-TKIs over EGFR-TKIs alone in both subgroups.
                     </p>
                     
                     <p id="p-14" class="indent">A sensitivity analysis was also conducted to examine the impact of the overall results from this study by limiting the analyses
                        on front-line trials that were known to have determined EGFR mutation based on exons 19 and 21 only.
                     </p>
                     
                     <p id="p-15" class="indent">We used the χ2 Cochran Q test to detect for heterogeneity across the different studies and between subgroups defined by EGFR
                        mutation status, study setting, and study design. The nominal level of significance was set at 5%. All 95% confidence intervals
                        were two-sided.
                     </p>
                     
                     <p id="p-16" class="indent">Cochrane Review Manager (version 5, Cochrane Collaboration, Copenhagen, Denmark, <a href="http://ims.cochrane.org/home">http://ims.cochrane.org/home</a>) was used for all analyses.
                     </p>
                     
                  </div>
                  
               </div>
               <div class="section" id="sec-9">
                  <div class="section-nav"><a href="#sec-5" title="Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-15" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Results</h2>
                  
                  <p id="p-17">The search strategy identified 40 studies, of which 23 (<a id="xref-ref-12-2" class="xref-bibr" href="#ref-12">12–14</a>,<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16–44</a>) were eligible for inclusion in this meta-analysis (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Figure 1</a>). Trial data were obtained from published manuscripts and conference abstracts for 19 trials, and additional data on treatment
                     efficacy by EGFRmut<sup>+</sup> and EGFRmut<sup>–</sup> subgroups were obtained directly from study investigators for four studies [ISEL (<a id="xref-ref-41-1" class="xref-bibr" href="#ref-41">41</a>), V-15-32 (<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>), TOPICAL (<a id="xref-ref-43-1" class="xref-bibr" href="#ref-43">43</a>), and IFCT-GFPC 0502 (<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>, <a id="xref-ref-44-1" class="xref-bibr" href="#ref-44">44)</a>]. Treatment estimates for the TALENT study (<a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>) were calculated on the basis of data extracted from presented survival curves. The hazard ratios for OS for ISEL (<a id="xref-ref-41-2" class="xref-bibr" href="#ref-41">41</a>), IFCT-GFPC 0502 (<a id="xref-ref-32-2" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-44-2" class="xref-bibr" href="#ref-44">44)</a>, and V-15–32 (<a id="xref-ref-31-2" class="xref-bibr" href="#ref-31">31</a>) were estimated on the basis of the observed number of deaths. In all other studies, hazard ratios and associated variances
                     were obtained directly from trial reports.
                  </p>
                  
                  <div id="F1" class="fig pos-float type-figure  odd">
                     <div class="fig-inline"><a href="595/F1.expansion.html"><img alt="Figure 1." src="595/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="595/F1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="595/F1.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/105/9/595/F1">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label">Figure 1.</span> 
                        
                        <p id="p-18" class="first-child">Flow diagram showing inclusion and exclusion of studies. EGFR = epidermal growth factor receptor.</p>
                        
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-19" class="indent">A total of 14570 patients participated in these 23 trials. EGFR mutation status, as determined by mutation analysis only,
                     was known for at least 31% (n = 4473) of trial patients. [In the TALENT study (<a id="xref-ref-37-2" class="xref-bibr" href="#ref-37">37</a>), the treatment comparisons for the subgroups were reported, but the number of patients in each subgroup was unknown.] Clinicopathological
                     and demographic characteristics of patients enrolled in these studies are summarized in <a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>.
                  </p>
                  
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="595/T1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="595/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">Table 1.</span> 
                        
                        <p id="p-20" class="first-child">Demographic characteristics of patients*</p>
                        
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-25" class="indent">Trials investigated EGFR-TKIs for front-line therapy in treatment-naive patients (n = 13 trials), second-line or subsequent
                     treatment after failure of chemotherapy (n = 7 trials), and maintenance treatment in patients with nonprogressive disease
                     after front-line chemotherapy (n = 3 trials). Among the 13 front-line studies, eight compared EGFR-TKIs as monotherapy vs
                     chemotherapy (<a id="xref-ref-16-2" class="xref-bibr" href="#ref-16">16–21</a>,<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>,<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a>,<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33–35</a>,<a id="xref-ref-38-1" class="xref-bibr" href="#ref-38">38</a>), four compared EGFR-TKIs with chemotherapy vs chemotherapy alone (<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>,<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24–26</a>,<a id="xref-ref-37-3" class="xref-bibr" href="#ref-37">37</a>,<a id="xref-ref-45-1" class="xref-bibr" href="#ref-45">45)</a>, and one was a placebo-controlled trial (<a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>,<a id="xref-ref-43-2" class="xref-bibr" href="#ref-43">43)</a>. Among the seven second-line and subsequent treatment trials, five compared EGFR-TKIs as monotherapy vs chemotherapy (<a id="xref-ref-12-3" class="xref-bibr" href="#ref-12">12</a>,<a id="xref-ref-14-2" class="xref-bibr" href="#ref-14">14</a>,<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>,<a id="xref-ref-31-3" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-42-1" class="xref-bibr" href="#ref-42">42)</a>, and two were placebo-controlled studies (<a id="xref-ref-39-1" class="xref-bibr" href="#ref-39">39–41</a>). All three maintenance studies had a placebo arm (<a id="xref-ref-13-2" class="xref-bibr" href="#ref-13">13</a>,<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-3" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-44-3" class="xref-bibr" href="#ref-44">44)</a>.
                  </p>
                  
                  <div id="sec-10" class="subsection">
                     
                     <h3>Benefit of EGFR-TKIs on PFS in Different Settings</h3>
                     
                     <p id="p-26">Data on PFS were available from 21 trials except ISEL (<a id="xref-ref-41-3" class="xref-bibr" href="#ref-41">41</a>) and BR21 (<a id="xref-ref-39-2" class="xref-bibr" href="#ref-39">39</a>). The treatment effect of EGFR-TKIs in different settings is shown in <a id="xref-fig-2-1" class="xref-fig" href="#F2">Figure 2</a>. The test of interaction between treatment and EGFR mutation status was statistically significant (front-line setting: <em>P</em> &lt; .001; second-line or subsequent treatment: <em>P</em> &lt; .001).
                     </p>
                     
                     <div id="F2" class="fig pos-float type-figure  odd">
                        <div class="fig-inline"><a href="595/F2.expansion.html"><img alt="Figure 2." src="595/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="595/F2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="595/F2.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/105/9/595/F2">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 2.</span> 
                           
                           <p id="p-27" class="first-child">Forest plot of hazard ratios comparing progression-free survival in subgroups of epidermal growth factor receptor (EGFR) mutation–
                              positive (EGFRmut<sup>+</sup>) and EGFR mutation–negative (EGFRmut<sup>–</sup>) patients who received EGFR–tyrosine kinase inhibitors (TKIs) vs control. Hazard ratios for each trial are represented by
                              the <strong>squares</strong>, and the <strong>horizontal line</strong> crossing the square represents the 95% confidence interval (CI). The <strong>diamonds</strong> represent the estimated overall effect based on the meta-analysis fixed effect of the trials. All statistical tests were
                              two-sided.
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                     <p id="p-28" class="indent">In EGFRmut<sup>+</sup> patients, EGFR-TKIs treatment was associated with a lower risk of disease progression in the front-line setting (HR = 0.43;
                        95% CI = 0.38 to 0.49; <em>P</em> &lt; .001) and second-line or subsequent treatment (HR = 0.34; 95% CI = 0.20 to 0.60; <em>P</em> &lt; .001).
                     </p>
                     
                     <p id="p-29" class="indent">In EGFRmut<sup>–</sup> patients, EGFR-TKIs did not show a treatment advantage in the front-line setting or beyond. There was no statistically significant
                        difference between EGFR-TKIs and chemotherapy in reducing the risk of disease progression in front-line therapy (HR = 1.06;
                        95% CI = 0.94 to 1.19; <em>P</em> = .35). EGFR-TKIs treatment was statistically significantly inferior to chemotherapy in second-line or subsequent therapy
                        (HR = 1.23; 95% CI = 1.05 to 1.46; <em>P</em> = .01).
                     </p>
                     
                     <p id="p-30" class="indent">Maintenance therapy with EGFR-TKIs compared with placebo was effective in reducing the risk of disease progression in EGFRmut<sup>+</sup> and EGFRmut<sup>–</sup> subgroups (EGFRmut<sup>+</sup>: HR = 0.15, 95% CI = 0.08 to 0.27, <em>P</em> &lt; .001; EGFRmut<sup>–</sup>: HR = 0.81, 95% CI = 0.68 to 0.97, <em>P</em> = .02). The test of interaction between treatment and EGFR mutation status was statistically significant (<em>P</em> &lt; .001).
                     </p>
                     
                  </div>
                  
                  <div id="sec-11" class="subsection">
                     
                     <h3>Effect of EGFR-TKIs Combined With Chemotherapy on PFS</h3>
                     
                     <p id="p-31">Data were available for four trials [INTACT 1 and 2 (<a id="xref-ref-45-2" class="xref-bibr" href="#ref-45">45</a>), TRIBUTE (<a id="xref-ref-22-2" class="xref-bibr" href="#ref-22">22</a>) and TALENT (<a id="xref-ref-37-4" class="xref-bibr" href="#ref-37">37</a>)] that combined EGFR-TKIs with chemotherapy. Combination EGFR-TKIs and chemotherapy compared with chemotherapy alone was
                        effective in reducing the risk of disease progression in both subgroups (EGFRmut<sup>+</sup>: HR = 0.54, 95% CI = 0.30 to 0.95, <em>P</em> = .04; EGFRmut<sup>–</sup>: HR = 0.82, 95% CI = 0.68 to 0.98, <em>P</em> = .03; treatment-by-EGFR mutation status interaction: <em>P</em> = .17) (<a id="xref-fig-3-1" class="xref-fig" href="#F3">Figure 3</a>). When EGFR-TKIs monotherapy was compared with chemotherapy, EGFR-TKIs treatment was associated with a reduced risk of disease
                        progression in the EGFRmut<sup>+</sup> subgroup (HR = 0.42; 95% CI = 0.37 to 0.48; <em>P</em> &lt; .001) but an increased risk in the EGFRmut<sup>-</sup> subgroup (HR = 1.56; 95% CI = 1.36 to 1.80; <em>P</em> &lt; .001).
                     </p>
                     
                     <div id="F3" class="fig pos-float type-figure  odd">
                        <div class="fig-inline"><a href="595/F3.expansion.html"><img alt="Figure 3." src="595/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="595/F3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="595/F3.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/105/9/595/F3">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 3.</span> 
                           
                           <p id="p-32" class="first-child">Forest plot of hazard ratios comparing progression-free survival in subgroups of epidermal growth factor receptor (EGFR) mutation–positive
                              (EGFRmut<sup>+</sup>) and EGFR mutation–negative (EGFRmut<sup>–</sup>) patients who received EGFR–tyrosine kinase inhibitors (TKIs) and chemotherapy vs chemotherapy. Hazard ratios for each trial
                              are represented by the <strong>squares</strong>, and the <strong>horizontal line</strong> crossing the square represents the 95% confidence interval (CI). The <strong>diamonds</strong> represent the estimated overall effect based on the meta-analysis fixed effect of the trials. All statistical tests were
                              two-sided.
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                     <p id="p-33" class="indent">Within the EGFRmut<sup>+</sup> subgroup, an indirect comparison of data available from these trials indicates EGFR-TKIs treatment in combination with chemotherapy
                        was not more effective than EGFR-TKIs alone in reducing the risk of disease progression (HR = 1.42; 95% CI = 0.80 to 2.53;
                        <em>P</em> = .23). By contrast, within the EGFRmut<sup>–</sup> subgroup, EGFR-TKIs treatment in combination with chemotherapy was more effective in reducing the risk of disease progression
                        than EGFR-TKIs alone (HR = 0.51; 95% CI = 0.43 to 0.62; <em>P</em> &lt; .001).
                     </p>
                     
                  </div>
                  
                  <div id="sec-12" class="subsection">
                     
                     <h3>Effect of EGFR-TKIs on OS in Different Settings</h3>
                     
                     <p id="p-34">Data on OS were available from 19 trials except Lux Lung 3 (<a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a>), TAILOR (<a id="xref-ref-14-3" class="xref-bibr" href="#ref-14">14</a>), KCSG-LU08-01 (<a id="xref-ref-42-2" class="xref-bibr" href="#ref-42">42</a>), and INFORM (<a id="xref-ref-30-2" class="xref-bibr" href="#ref-30">30</a>). Subgroup analyses by treatment setting are summarized in <a id="xref-fig-4-1" class="xref-fig" href="#F4">Figure 4</a>. The test interaction for treatment and EGFR mutation status was not statistically significant (front-line setting: <em>P</em> = .91; second-line or subsequent therapy: <em>P</em> = .37). For EGFRmut<sup>+</sup> patients, there was no treatment advantage of EGFR-TKIs in the front-line setting (HR = 1.01; 95% CI = 0.87 to 1.18; <em>P</em> = .86) or for second-line or subsequent therapy (HR = 0.74; 95% CI = 0.45 to 1.19; <em>P</em> = .21) in the risk of death. Similar results were observed in EGFRmut<sup>-</sup> patients.
                     </p>
                     
                     <div id="F4" class="fig pos-float type-figure  odd">
                        <div class="fig-inline"><a href="595/F4.expansion.html"><img alt="Figure 4." src="595/F4.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="595/F4.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="595/F4.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/105/9/595/F4">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 4.</span> 
                           
                           <p id="p-35" class="first-child">Forest plot of hazard ratios comparing overall survival in subgroups of epidermal growth factor receptor (EGFR) mutation–positive
                              (EGFRmut<sup>+</sup>) and EGFR mutation–negative (EGFRmut<sup>–</sup>) patients who received EGFR–tyrosine kinase inhibitors (TKIs) vs control. Hazard ratios for each trial are represented by
                              the <strong>squares</strong>, and the <strong>horizontal line</strong> crossing the square represents the 95% confidence interval (CI). The <strong>diamonds</strong> represent the estimated overall effect based on the meta-analysis fixed effect of the trials. All statistical tests were
                              two-sided.
                           </p>
                           
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     
                     <p id="p-36" class="indent">Only two studies [SATURN (<a id="xref-ref-13-3" class="xref-bibr" href="#ref-13">13</a>) and IFCT-GFPC 0502 (<a id="xref-ref-32-4" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-44-4" class="xref-bibr" href="#ref-44">44)</a>] reported OS in the maintenance setting. There was no clear benefit of treatment with EGFR-TKIs over placebo in either EGFRmut<sup>+</sup> patients (HR = 0.78; 95% CI = 0.33 to 1.84; <em>P</em> = .57) or EGFRmut<sup>-</sup> patients (HR = 0.84; 95% CI = 0.69 to 1.04; <em>P</em> = .10). The test for interaction between treatment and EGFR mutation status was not statistically significant (<em>P</em> = .87).
                     </p>
                     
                  </div>
                  
                  <div id="sec-13" class="subsection">
                     
                     <h3>Publication Bias</h3>
                     
                     <p id="p-37">In this meta-analysis, the overall treatment effect was not statistically significant for the OS outcome. Any potential publication
                        bias through the exclusion of non–statistically significant studies would therefore not have influenced these results.
                     </p>
                     
                  </div>
                  
                  <div id="sec-14" class="subsection">
                     
                     <h3>Sensitivity Analysis</h3>
                     
                     <p id="p-38">EGFR mutation, based on exons 19 and 21 only, was known to have been examined in three trials in a front-line setting (<a id="xref-table-wrap-1-2" class="xref-table" href="#T1">Table 1</a>). One trial (<a id="xref-ref-34-2" class="xref-bibr" href="#ref-34">34</a>) provided the treatment estimate for PFS limited to patients with exons 19 and 21 only. In the front-line setting, similar
                        qualitative results were obtained when the analyses were limited to only these four trials on PFS and OS outcomes for the
                        EGFRmut<sup>+</sup> subgroup (<a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/djt072/-/DC1">Supplementary Figures 1</a> and <a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/djt072/-/DC1">2</a>, available online).
                     </p>
                     
                  </div>
                  
               </div>
               <div class="section" id="sec-15">
                  <div class="section-nav"><a href="#sec-9" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-16" title="Funding" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Discussion</h2>
                  
                  <p id="p-39">This study extends the analysis beyond prior publications of the most clinically important molecular factor relevant to the
                     treatment of NSCLC. Increased confidence in the findings is evident through the incorporation of results from 23 trials in
                     nearly 15000 patients with more than 4000 having molecular analysis. Additionally, this study approached issues not addressed
                     in prior meta-analyses. As such, results from this study have implications for treatment and for study interpretation and
                     design.
                  </p>
                  
                  <p id="p-40" class="indent">This meta-analysis summarizes the best available evidence to guide the use of EGFR-TKIs in patients with advanced NSCLC. EGFR-TKIs
                     treatment is associated with 57% and 66% reduction in the risk of disease progression in EGFRmut<sup>+</sup> patients in front-line and second-line settings, respectively, but with no benefit in EGFRmut<sup>-</sup> patients (<a id="xref-fig-2-2" class="xref-fig" href="#F2">Figure 2</a>). This study also demonstrates that EGFR mutation is an important predictive biomarker of TKIs treatment benefit in terms
                     of PFS for all settings: front-line, maintenance, and second-line or subsequent therapy. This study demonstrates for the first
                     time that the magnitude of effect on PFS for EGFRmut<sup>+</sup> patients is similar in patients receiving EGFR-TKIs in either the first- or second-line setting (HR = 0.43 and 0.34, respectively).
                  </p>
                  
                  <p id="p-41" class="indent">Even with mutational analyses in more than 4000 patients and with a large PFS benefit, this meta-analysis does not demonstrate
                     OS advantage with EGFR-TKIs. Regardless of EGFR mutation status, the overall treatment effects on OS were similar. The  frequently
                     suggested reason for this lack of OS effect is the confounding effect of postprogression therapy between the randomization
                     arms. None of the front-line trials prohibited patients from crossing over to the other treatment arm, and crossover was increasingly
                     frequent over the decade during which these trials were conducted. For example, the NEJ002 trial randomly assigned patients
                     to receive either gefitinib or chemotherapy. Not only did most patients receive subsequent treatment, but 94.6% of patients
                     in the chemotherapy arm were reported to have received second-line gefitinib on disease progression (<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>). A recent systematic review of chemotherapy trials also indicated that PFS advantage is unlikely to be associated with an
                     OS advantage with increasing impact of salvage therapy and that the prolongation of survival postprogression might limit the
                     role of OS for assessing true efficacy derived from front-line therapy (<a id="xref-ref-46-1" class="xref-bibr" href="#ref-46">46</a>). Moreover, analysis of a recent trial indicated that compared with EGFRmut<sup>–</sup> patients, twice as many EGFRmut<sup>+</sup> patients responded to chemotherapy (<a id="xref-ref-28-2" class="xref-bibr" href="#ref-28">28</a>). Crossover effects, lack of blinding in experimental arms, and other factors that have been previously discussed can make
                     PFS a difficult surrogate for OS (<a id="xref-ref-47-1" class="xref-bibr" href="#ref-47">47–49</a>). Ongoing work is still required to demonstrate the impact of other clinically meaningful benefits of EGFR-TKIs beyond survival
                     and PFS for these patients.
                  </p>
                  
                  <p id="p-42" class="indent">Controversy continues regarding the role of the addition of EGFR-TKIs in patients receiving chemotherapy. For this reason,
                     we analyzed this issue in four large, published, prospective, randomized trials in front-line treatment [INTACT 1 and 2 (<a id="xref-ref-45-3" class="xref-bibr" href="#ref-45">45</a>), TALENT (<a id="xref-ref-37-5" class="xref-bibr" href="#ref-37">37</a>), and TRIBUTE (<a id="xref-ref-22-3" class="xref-bibr" href="#ref-22">22</a>)]. Pooled results from these four front-line trials showed that combining EGFR-TKIs with chemotherapy over chemotherapy alone
                     statistically significantly delayed disease progression in both the EGFRmut<sup>+</sup> and EGFRmut<sup>–</sup> subgroups. Preclinical studies (<a id="xref-ref-50-1" class="xref-bibr" href="#ref-50">50</a>,<a id="xref-ref-51-1" class="xref-bibr" href="#ref-51">51)</a> have demonstrated a synergistic effect of combining EGFR-TKIs with chemotherapy. However, indirect comparison of trial arms
                     suggests that combined EGFR-TKIs treatment and chemotherapy is not more effective than EGFR-TKIs alone in reducing the risk
                     of disease progression in EGFRmut<sup>+</sup> patients (HR = 1.42; 95% CI = 0.80 to 2.53; <em>P</em> = .23). A lack of additional benefit was confirmed in a prospective phase II trial (<a id="xref-ref-52-1" class="xref-bibr" href="#ref-52">52</a>) in which erlotinib monotherapy was compared with erlotinib chemotherapy combination in the EGFRmut<sup>+</sup> subgroup (median PFS 14.1 vs 17.2 months).
                  </p>
                  
                  <p id="p-43" class="indent">This meta-analysis provides information to define better the relative effectiveness of EGFR-TKIs for EGFRmut<sup>–</sup> patients. In front-line therapy, there was a non–statistically significant difference between EGFR-TKIs and control in reducing
                     the risk of disease progression (pooled HR = 1.06; <em>P</em> = .35). This finding is consistent with previous in vitro studies that demonstrated a lack of sensitivity of wild-type EGFRmut<sup>–</sup> receptor lung tumor to EGFR-TKIs treatment (<a id="xref-ref-4-2" class="xref-bibr" href="#ref-4">4–6</a>). Although a small benefit of EGFR-TKIs over placebo in the EGFRmut<sup>–</sup> subgroup has been demonstrated in three maintenance studies [SATURN (<a id="xref-ref-13-4" class="xref-bibr" href="#ref-13">13</a>), INFORM (<a id="xref-ref-30-3" class="xref-bibr" href="#ref-30">30</a>), and IFCT-GFPC 0502 (<a id="xref-ref-32-5" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-44-5" class="xref-bibr" href="#ref-44">44)</a>] (pooled HR = 0.81; 95% CI = 0.68 to 0.97; <em>P</em> = .02), it must be realized that this benefit is markedly and both clinically and statistically significantly greater in
                     EGFRmut<sup>+</sup> subgroups (pooled HR = 0.15; 95% CI = 0.08 to 0.27; <em>P</em> &lt; .001), and the test of interaction between EGFR mutation status and treatment is highly statistically significant (<em>P</em> &lt; .001).
                  </p>
                  
                  <p id="p-44" class="indent">This meta-analysis also examined the role of EGFR mutation in selecting patients for second-line or subsequent treatment.
                     A 2012 editorial has illustrated the debate in this area (<a id="xref-ref-53-1" class="xref-bibr" href="#ref-53">53</a>). Although trials have differed in their results, one study (TAILOR) reported that chemotherapy was statistically significantly
                     superior over erlotinib in terms of tumor response and PFS (OS results are not yet available) in patients without EGFR mutations
                     in exon 19 or 21 undergoing second-line treatment, but the data remain premature and only available as a conference presentation
                     (<a id="xref-ref-14-4" class="xref-bibr" href="#ref-14">14</a>). In the current meta-analysis, pooled results from trials of second-line and subsequent therapies demonstrated that treatment
                     with EGFR-TKIs treatment, compared with chemotherapy, was associated with a 66% reduction in the risk of disease progression
                     in the EGFRmut<sup>+</sup> subgroup (<a id="xref-fig-2-3" class="xref-fig" href="#F2">Figure 2</a>). In contrast, EGFR-TKIs treatment,  compared with chemotherapy, was 23% inferior (<a id="xref-fig-2-4" class="xref-fig" href="#F2">Figure 2</a>) in delaying disease progression (but not OS) in EGFRmut<sup>–</sup> patients with good performance status who were suitable to receive chemotherapy. The test of interaction between EGFR mutation
                     status and second-line or subsequent treatment was statistically significant (<em>P</em> &lt; .001), suggesting that EGFR mutation is still an important treatment effect modifier and should be used to guide treatment
                     decisions in this setting. Interestingly, updated results from the TOPICAL trial demonstrated that rash during the first cycle
                     predicted PFS benefits with erlotinib in the EGFRmut<sup>–</sup> subgroup (<a id="xref-ref-43-3" class="xref-bibr" href="#ref-43">43</a>).
                  </p>
                  
                  <p id="p-45" class="indent">This meta-analysis has several strengths. We performed a comprehensive review, reported the most up-to-date published data,
                     and contacted individual investigators to obtain relevant unpublished data. By examining both the EGFRmut<sup>+</sup> and EGFRmut<sup>–</sup> subgroups, the value of EGFR mutation status as a treatment effect modifier can be adequately assessed. This meta-analysis
                     also overcomes the problem of inadequate power of individual studies to compare subgroups. For example, only six studies (<a id="xref-ref-16-3" class="xref-bibr" href="#ref-16">16</a>,<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>,<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>,<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>,<a id="xref-ref-34-3" class="xref-bibr" href="#ref-34">34</a>,<a id="xref-ref-38-2" class="xref-bibr" href="#ref-38">38)</a> included in this review had EGFRmut<sup>+</sup> results for more than 50 patients. Reliable interpretation of independent treatment effects in most of the individual studies
                     in this review is not possible because of small sample sizes. Altogether, more than 4000 patients with mutational analysis
                     were included in this study. A major strength of this current meta-analysis is that the pooled results allow examination of
                     second-line and maintenance treatment as well as elucidation of the effect of adding EGFR-TKIs to chemotherapy.
                  </p>
                  
                  <p id="p-46" class="indent">There are also limitations that should be noted from this analysis. Firstly, we assumed that all EGFR-TKIs, including gefitinib,
                     erlotinib, and afatinib, have equivalent therapeutic efficacy for both the EGFRmut<sup>+</sup> and EGFRmut<sup>–</sup> subgroups. Secondly, EGFR mutation status was only assessed in 31% of patients enrolled in eligible trials, with treatment
                     efficacy estimated from small numbers of EGFRmut<sup>+</sup> patients identified in many of these trials (<a id="xref-table-wrap-1-3" class="xref-table" href="#T1">Table 1</a>). The potential influence on the results of restricting our analyses to this subset of patients is unknown. We further obtained
                     efficacy data in the subgroups with known EGFR mutation status through personal communication with investigators of four trials
                     (<a id="xref-ref-31-4" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-32-6" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-41-4" class="xref-bibr" href="#ref-41">41</a>,<a id="xref-ref-43-4" class="xref-bibr" href="#ref-43">43)</a>. Although these subgroup data have not been published, the primary trial outcomes of these studies have been peer reviewed.
                     Although nearly 15000 patients were included in the analysis, the fact that only a minority had reported mutational analysis
                     limits the ability to address several issues. Sequencing was the most commonly used method to detect EGFR mutation, and it
                     has poor sensitivity in detecting EGFR mutant alleles in DNA samples extracted from tumors (<a id="xref-ref-54-1" class="xref-bibr" href="#ref-54">54</a>). These DNA samples may contain both malignant and nonmalignant (from adjacent normal or tumor stroma) cells and hence may
                     impact the outcome of this meta-analysis through misclassification of patients’ EGFR mutation status. Moreover, mutation of
                     EGFR exons 19 and 21 are sensitizing mutations predictive of PFS benefit with EGFR-TKIs, whereas de novo mutations in exon
                     20 might reduce the effectiveness of EGFR-TKIs (<a id="xref-ref-55-1" class="xref-bibr" href="#ref-55">55–57</a>). In this meta-analysis, patients classified as EGFRmut<sup>+</sup> in some trials included those with mutations in exon 20. However, when we restricted our analysis to studies that classified
                     patients as EGFRmut<sup>+</sup> based on presence of EGFR exon 19 and exon 21 mutations, we observed similar quantitative results. In front-line therapy,
                     information on crossover and postprogression therapies was often not available, so adjustments could not be made to account
                     for the lack of OS benefit in EGFRmut<sup>+</sup> patients treated with EGFR-TKIs.
                  </p>
                  
                  <p id="p-47" class="indent">Many reports have confirmed that EGFR mutations are more commonly found in patients with adenocarcinoma and in patients with
                     low- and never-smoking histories. These factors have led to the debate as to whether knowledge of such demographic factors,
                     rather than use of molecular studies, would be sufficient for treatment. The current meta-analysis, which examines multiple
                     treatment settings, demonstrates that EGFR mutation status should guide personalization of treatment. Additionally, recent
                     findings have reported that these same demographic features are more common in other genetic differences [such as those associated
                     with EML-ALK  translocations (<a id="xref-ref-10-2" class="xref-bibr" href="#ref-10">10</a>) and ROS 1 mutations (<a id="xref-ref-11-2" class="xref-bibr" href="#ref-11">11</a>)] that are not beneficially affected by EGFR-TKIs and for which specific therapy is available. Determining mutational status
                     can avoid side effects of either EGFR-TKIs or chemotherapy and can lead to rational decision making. In that only the minority
                     of all patients with NSCLC will have EGFR or other treatment-altering mutations, and because nearly all lung cancer therapy
                     is costly, molecular analysis is increasingly important from clinical, scientific, and economic perspectives.
                  </p>
                  
                  <p id="p-48" class="indent">In conclusion, based on this meta-analysis, treatment with EGFR-TKIs statistically significantly delays disease progression
                     in EGFRmut<sup>+</sup> patients but has no demonstrable impact on OS. EGFR mutation is a predictive biomarker of benefit with EGFR-TKIs treatment
                     in delaying disease progression in front-line, second-line, and subsequent therapy and in maintenance settings. These findings
                     support assessment of EGFR mutation status before initiation of EGFR-TKIs treatment and indicate that EGFR-TKIs should be
                     considered as front-line therapy in EGFRmut<sup>+</sup> patients with advanced NSCLC.
                  </p>
                  
               </div>
               <div class="section" id="sec-16">
                  <div class="section-nav"><a href="#sec-15" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#notes-1" title="Notes" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>Funding</h2>
                  
                  <p id="p-49">This work was partially supported by an educational grant from Boehringer Ingelheim.</p>
                  
               </div>
               <div class="section notes" id="notes-1">
                  <div class="section-nav"><a href="#sec-16" title="Funding" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Notes</h2>
                  
                  <p id="p-50">We thank the investigators of ISEL, V-15-32, and IFCT-GFPC 0502, and AstraZeneca for providing us with unpublished data for
                     this meta-analysis. We also thank the members of the Australasian Lung Cancer Trials Group and Dr Sally Lord (NHMRC Clinical
                     Trials Centre) for the helpful comments. We acknowledge the editorial support provided by Ms Rhana Pike and Ms Stefanie Chuah.
                  </p>
                  
               </div>
               <ul class="copyright-statement">
                  <li class="fn" id="copyright-statement-1">© The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#notes-1" title="Notes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">1.</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1. in text"
                           id="ref-1">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.1"
                             data-doi="10.1097/01.JTO.0000263718.69320.4c">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sato</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shames</span>  <span class="cit-name-given-names">DS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gazdar</span>  <span class="cit-name-given-names">AF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Minna</span>  <span class="cit-name-given-names">JD</span></span></li>
                              </ol><cite>.
                                 <span class="cit-article-title">A translational view of the molecular pathogenesis of lung cancer</span>.
                                 <abbr class="cit-jnl-abbrev">J Thorac Oncol</abbr>.
                                 <span class="cit-pub-date">2007</span>;<span class="cit-vol">2</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">327</span>–<span class="cit-lpage">343</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/01.JTO.0000263718.69320.4c&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17409807&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000245564000015&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20translational%20view%20of%20the%20molecular%20pathogenesis%20of%20lung%20cancer&amp;author=M%20Sato&amp;author=DS%20Shames&amp;author=AF%20Gazdar&amp;author=JD%20Minna&amp;publication_year=2007&amp;journal=J%20Thorac%20Oncol&amp;volume=2&amp;issue=4&amp;pages=327-343">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">2.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.2"
                             data-doi="10.1038/nrc2190">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sun</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schiller</span>  <span class="cit-name-given-names">JH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gazdar</span>  <span class="cit-name-given-names">AF</span></span></li>
                              </ol><cite>.
                                 <span class="cit-article-title">Lung cancer in never smokers—a different disease</span>.
                                 <abbr class="cit-jnl-abbrev">Nat Rev Cancer</abbr>.
                                 <span class="cit-pub-date">2007</span>;<span class="cit-vol">7</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">778</span>–<span class="cit-lpage">790</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/nrc2190&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17882278&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000249691700014&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Lung%20cancer%20in%20never%20smokers%E2%80%94a%20different%20disease&amp;author=S%20Sun&amp;author=JH%20Schiller&amp;author=AF%20Gazdar&amp;publication_year=2007&amp;journal=Nat%20Rev%20Cancer&amp;volume=7&amp;issue=10&amp;pages=778-790">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">3.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.3">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tang</span>  <span class="cit-name-given-names">X</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shigematsu</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bekele</span>  <span class="cit-name-given-names">BN</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients</span>.
                                 <abbr class="cit-jnl-abbrev">Cancer Res</abbr>.
                                 <span class="cit-pub-date">2005</span>;<span class="cit-vol">65</span>(<span class="cit-issue">17</span>):<span class="cit-fpage">7568</span>–<span class="cit-lpage">7572</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=65/17/7568"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">4.</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4. in text"
                           id="ref-4">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.4"
                             data-doi="10.1056/NEJMoa040938">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lynch</span>  <span class="cit-name-given-names">TJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bell</span>  <span class="cit-name-given-names">DW</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sordella</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib</span>.
                                 <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>.
                                 <span class="cit-pub-date">2004</span>;<span class="cit-vol">350</span>(<span class="cit-issue">21</span>):<span class="cit-fpage">2129</span>–<span class="cit-lpage">2139</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa040938&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15118073&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000221496700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Activating%20mutations%20in%20the%20epidermal%20growth%20factor%20receptor%20underlying%20responsiveness%20of%20non%E2%80%93small-cell%20lung%20cancer%20to%20gefitinib&amp;author=TJ%20Lynch&amp;author=DW%20Bell&amp;author=R%20Sordella&amp;publication_year=2004&amp;journal=N%20Engl%20J%20Med&amp;volume=350&amp;issue=21&amp;pages=2129-2139">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">5.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.5"
                             data-doi="10.1126/science.1099314">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Paez</span>  <span class="cit-name-given-names">JG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jänne</span>  <span class="cit-name-given-names">PA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lee</span>  <span class="cit-name-given-names">JC</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span>.
                                 <abbr class="cit-jnl-abbrev">Science</abbr>.
                                 <span class="cit-pub-date">2004</span>;<span class="cit-vol">304</span>(<span class="cit-issue">5676</span>):<span class="cit-fpage">1497</span>–<span class="cit-lpage">1500</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=sci&amp;resid=304/5676/1497"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">6.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.6"
                             data-doi="10.1073/pnas.0405220101">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pao</span>  <span class="cit-name-given-names">W</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Miller</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zakowski</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors
                                    to gefitinib and erlotinib</span>.
                                 <abbr class="cit-jnl-abbrev">Proc Natl Acad Sci U S A</abbr>.
                                 <span class="cit-pub-date">2004</span>;<span class="cit-vol">101</span>(<span class="cit-issue">36</span>):<span class="cit-fpage">13306</span>–<span class="cit-lpage">13311</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=101/36/13306"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">7.</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text"
                           id="ref-7">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.7"
                             data-doi="10.1093/annonc/mdq742">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bria</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Milella</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cuppone</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy
                                    as first-line treatment: a meta-analysis</span>.
                                 <abbr class="cit-jnl-abbrev">Ann Oncol</abbr>.
                                 <span class="cit-pub-date">2011</span>;<span class="cit-vol">22</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">2277</span>–<span class="cit-lpage">2285</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=22/10/2277"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">8.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.8"
                             data-doi="10.1016/j.cllc.2011.08.005">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Petrelli</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Borgonovo</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cabiddu</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Barni</span>  <span class="cit-name-given-names">S</span></span></li>
                              </ol><cite>.
                                 <span class="cit-article-title">Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13
                                    randomized trials</span>.
                                 <abbr class="cit-jnl-abbrev">Clin Lung Cancer</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">13</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">107</span>–<span class="cit-lpage">114</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.cllc.2011.08.005&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22056888&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000301314700004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Efficacy%20of%20EGFR%20tyrosine%20kinase%20inhibitors%20in%20patients%20with%20EGFR-mutated%20non%E2%80%93small-cell%20lung%20cancer%3A%20a%20meta-analysis%20of%2013%20randomized%20trials&amp;author=F%20Petrelli&amp;author=K%20Borgonovo&amp;author=M%20Cabiddu&amp;author=S%20Barni&amp;publication_year=2012&amp;journal=Clin%20Lung%20Cancer&amp;volume=13&amp;issue=2&amp;pages=107-114">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">9.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.9"
                             data-doi="10.1002/ijc.27396">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gao</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ren</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Li</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell
                                    lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials</span>.
                                 <abbr class="cit-jnl-abbrev">Int J Cancer</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">131</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">E822</span>–<span class="cit-lpage">829</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/ijc.27396&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22161771&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000305756900023&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Epidermal%20growth%20factor%20receptor-tyrosine%20kinase%20inhibitor%20therapy%20is%20effective%20as%20first-line%20treatment%20of%20advanced%20non-small-cell%20lung%20cancer%20with%20mutated%20EGFR%3A%20a%20meta-analysis%20from%20six%20phase%20III%20randomized%20controlled%20trials&amp;author=G%20Gao&amp;author=S%20Ren&amp;author=A%20Li&amp;publication_year=2012&amp;journal=Int%20J%20Cancer&amp;volume=131&amp;issue=5&amp;pages=E822-829">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">10.</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text"
                           id="ref-10">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.10"
                             data-doi="10.1056/NEJMoa1006448">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kwak</span>  <span class="cit-name-given-names">EL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bang</span>  <span class="cit-name-given-names">Y-J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Camidge</span>  <span class="cit-name-given-names">DR</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer</span>.
                                 <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>.
                                 <span class="cit-pub-date">2010</span>;<span class="cit-vol">363</span>(<span class="cit-issue">18</span>):<span class="cit-fpage">1693</span>–<span class="cit-lpage">1703</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa1006448&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20979469&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000283546400004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Anaplastic%20lymphoma%20kinase%20inhibition%20in%20non%E2%80%93small-cell%20lung%20cancer&amp;author=EL%20Kwak&amp;author=Y-J%20Bang&amp;author=DR%20Camidge&amp;publication_year=2010&amp;journal=N%20Engl%20J%20Med&amp;volume=363&amp;issue=18&amp;pages=1693-1703">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">11.</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text"
                           id="ref-11">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.11">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shaw</span>  <span class="cit-name-given-names">AT</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Camidge</span>  <span class="cit-name-given-names">DR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Engelman</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-supplement">15 suppl</span>):<span class="cit-fpage">7508</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Clinical%20activity%20of%20crizotinib%20in%20advanced%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%20harboring%20ROS1%20gene%20rearrangement&amp;author=AT%20Shaw&amp;author=DR%20Camidge&amp;author=JA%20Engelman&amp;publication_year=2012&amp;journal=J%20Clin%20Oncol&amp;volume=30&amp;pages=7508">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">12.</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text"
                           id="ref-12">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.12"
                             data-doi="10.1016/S1470-2045(11)70385-0">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ciuleanu</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stelmakh</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cicenas</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung
                                    cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study</span>.
                                 <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">13</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">300</span>–<span class="cit-lpage">308</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(11)70385-0&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22277837&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000300880600038&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20erlotinib%20versus%20chemotherapy%20in%20second-line%20treatment%20of%20patients%20with%20advanced%2C%20non-small-cell%20lung%20cancer%20with%20poor%20prognosis%20%28TITAN%29%3A%20a%20randomised%20multicentre%2C%20open-label%2C%20phase%203%20study&amp;author=T%20Ciuleanu&amp;author=L%20Stelmakh&amp;author=S%20Cicenas&amp;publication_year=2012&amp;journal=Lancet%20Oncol&amp;volume=13&amp;issue=3&amp;pages=300-308">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">13.</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text"
                           id="ref-13">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.13"
                             data-doi="10.1016/S1470-2045(10)70112-1">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cappuzzo</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ciuleanu</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stelmakh</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase
                                    3 study</span>.
                                 <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>.
                                 <span class="cit-pub-date">2010</span>;<span class="cit-vol">11</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">521</span>–<span class="cit-lpage">529</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(10)70112-1&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20493771&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000279019500024&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Erlotinib%20as%20maintenance%20treatment%20in%20advanced%20non-small-cell%20lung%20cancer%3A%20a%20multicentre%2C%20randomised%2C%20placebo-controlled%20phase%203%20study&amp;author=F%20Cappuzzo&amp;author=T%20Ciuleanu&amp;author=L%20Stelmakh&amp;publication_year=2010&amp;journal=Lancet%20Oncol&amp;volume=11&amp;issue=6&amp;pages=521-529">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">14.</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text"
                           id="ref-14">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.14">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Garassino</span>  <span class="cit-name-given-names">MC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Martelli</span>  <span class="cit-name-given-names">O</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bettini</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">TAILOR: phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt)
                                    EGFR</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-supplement">15 suppl</span>):<span class="cit-fpage">LBA7501</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=TAILOR%3A%20phase%20III%20trial%20comparing%20erlotinib%20with%20docetaxel%20in%20the%20second-line%20treatment%20of%20NSCLC%20patients%20with%20wild-type%20%28wt%29%20EGFR&amp;author=MC%20Garassino&amp;author=O%20Martelli&amp;author=A%20Bettini&amp;publication_year=2012&amp;journal=J%20Clin%20Oncol&amp;volume=30&amp;pages=LBA7501">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">15.</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15. in text"
                           id="ref-15">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.15"
                             data-doi="10.1002/(SICI)1097-0258(19981230)17:24&lt;2815::AID-SIM110&gt;3.0.CO;2-8">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Parmar</span>  <span class="cit-name-given-names">MK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Torri</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stewart</span>  <span class="cit-name-given-names">L</span></span></li>
                              </ol><cite>.
                                 <span class="cit-article-title">Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</span>.
                                 <abbr class="cit-jnl-abbrev">Stat Med</abbr>.
                                 <span class="cit-pub-date">1998</span>;<span class="cit-vol">17</span>(<span class="cit-issue">24</span>):<span class="cit-fpage">2815</span>–<span class="cit-lpage">2834</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0258(19981230)17:24%3C2815::AID-SIM110%3E3.0.CO;2-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9921604&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077527600003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Extracting%20summary%20statistics%20to%20perform%20meta-analyses%20of%20the%20published%20literature%20for%20survival%20endpoints&amp;author=MK%20Parmar&amp;author=V%20Torri&amp;author=L%20Stewart&amp;publication_year=1998&amp;journal=Stat%20Med&amp;volume=17&amp;issue=24&amp;pages=2815-2834">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">16.</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16. in text"
                           id="ref-16">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.16"
                             data-doi="10.1016/S1470-2045(11)70184-X">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zhou</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wu</span>  <span class="cit-name-given-names">Y-L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chen</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung
                                    cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study</span>.
                                 <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>.
                                 <span class="cit-pub-date">2011</span>;<span class="cit-vol">12</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">735</span>–<span class="cit-lpage">742</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(11)70184-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=21783417&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000293272100024&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Erlotinib%20versus%20chemotherapy%20as%20first-line%20treatment%20for%20patients%20with%20advanced%20EGFR%20mutation-positive%20non-small-cell%20lung%20cancer%20%28OPTIMAL%2C%20CTONG-0802%29%3A%20a%20multicentre%2C%20open-label%2C%20randomised%2C%20phase%203%20study&amp;author=C%20Zhou&amp;author=Y-L%20Wu&amp;author=G%20Chen&amp;publication_year=2011&amp;journal=Lancet%20Oncol&amp;volume=12&amp;issue=8&amp;pages=735-742">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">17.</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17. in text"
                           id="ref-17">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.17"
                             data-doi="10.1056/NEJMoa0909530">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Maemondo</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Inoue</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kobayashi</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR</span>.
                                 <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>.
                                 <span class="cit-pub-date">2010</span>;<span class="cit-vol">362</span>(<span class="cit-issue">25</span>):<span class="cit-fpage">2380</span>–<span class="cit-lpage">2388</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa0909530&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20573926&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000279043800007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gefitinib%20or%20chemotherapy%20for%20non%E2%80%93small-cell%20lung%20cancer%20with%20mutated%20EGFR&amp;author=M%20Maemondo&amp;author=A%20Inoue&amp;author=K%20Kobayashi&amp;publication_year=2010&amp;journal=N%20Engl%20J%20Med&amp;volume=362&amp;issue=25&amp;pages=2380-2388">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">18.</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18. in text"
                           id="ref-18">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.18"
                             data-doi="10.1016/S1470-2045(11)70393-X">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rosell</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Carcereny</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gervais</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive
                                    non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial</span>.
                                 <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">13</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">239</span>–<span class="cit-lpage">246</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(11)70393-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22285168&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000300880600031&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Erlotinib%20versus%20standard%20chemotherapy%20as%20first-line%20treatment%20for%20European%20patients%20with%20advanced%20EGFR%20mutation-positive%20non-small-cell%20lung%20cancer%20%28EURTAC%29%3A%20a%20multicentre%2C%20open-label%2C%20randomised%20phase%203%20trial&amp;author=R%20Rosell&amp;author=E%20Carcereny&amp;author=R%20Gervais&amp;publication_year=2012&amp;journal=Lancet%20Oncol&amp;volume=13&amp;issue=3&amp;pages=239-246">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">19.</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19. in text"
                           id="ref-19">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.19"
                             data-doi="10.1056/NEJMoa0810699">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mok</span>  <span class="cit-name-given-names">TS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wu</span>  <span class="cit-name-given-names">Y-L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thongprasert</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma</span>.
                                 <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>.
                                 <span class="cit-pub-date">2009</span>;<span class="cit-vol">361</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">947</span>–<span class="cit-lpage">957</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa0810699&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=19692680&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000269480400004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gefitinib%20or%20carboplatin%E2%80%93paclitaxel%20in%20pulmonary%20adenocarcinoma&amp;author=TS%20Mok&amp;author=Y-L%20Wu&amp;author=S%20Thongprasert&amp;publication_year=2009&amp;journal=N%20Engl%20J%20Med&amp;volume=361&amp;issue=10&amp;pages=947-957">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">20.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.20"
                             data-doi="10.1200/JCO.2010.33.4235">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fukuoka</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wu</span>  <span class="cit-name-given-names">Y-L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thongprasert</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib
                                    versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS)</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2011</span>;<span class="cit-vol">29</span>(<span class="cit-issue">21</span>):<span class="cit-fpage">2866</span>–<span class="cit-lpage">2874</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=29/21/2866"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">21.</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21. in text"
                           id="ref-21">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.21"
                             data-doi="10.1016/S1470-2045(09)70364-X">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mitsudomi</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Morita</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Yatabe</span>  <span class="cit-name-given-names">Y</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal
                                    growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</span>.
                                 <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>.
                                 <span class="cit-pub-date">2010</span>;<span class="cit-vol">11</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">121</span>–<span class="cit-lpage">128</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(09)70364-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20022809&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000275152900019&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gefitinib%20versus%20cisplatin%20plus%20docetaxel%20in%20patients%20with%20non-small-cell%20lung%20cancer%20harbouring%20mutations%20of%20the%20epidermal%20growth%20factor%20receptor%20%28WJTOG3405%29%3A%20an%20open%20label%2C%20randomised%20phase%203%20trial&amp;author=T%20Mitsudomi&amp;author=S%20Morita&amp;author=Y%20Yatabe&amp;publication_year=2010&amp;journal=Lancet%20Oncol&amp;volume=11&amp;issue=2&amp;pages=121-128">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">22.</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22. in text"
                           id="ref-22">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.22"
                             data-doi="10.1200/JCO.2005.02.840">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Herbst</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Prager</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hermann</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced
                                    non–small-cell lung cancer</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>(<span class="cit-issue">25</span>):<span class="cit-fpage">5892</span>–<span class="cit-lpage">5899</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/25/5892"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">23.</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference 23. in text"
                           id="ref-23">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.23"
                             data-doi="10.1200/JCO.2011.36.8456">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Han</span>  <span class="cit-name-given-names">J-Y</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Park</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kim</span>  <span class="cit-name-given-names">S-W</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of
                                    the lung</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">1122</span>–<span class="cit-lpage">1128</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=30/10/1122"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">24.</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24. in text"
                           id="ref-24">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.24"
                             data-doi="10.1200/JCO.2004.08.001">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Giaccone</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Herbst</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Manegold</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2004</span>;<span class="cit-vol">22</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">777</span>–<span class="cit-lpage">784</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=22/5/777"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">25.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.25"
                             data-doi="10.1200/JCO.2004.07.215">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Herbst</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Giaccone</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schiller</span>  <span class="cit-name-given-names">JH</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT
                                    2</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2004</span>;<span class="cit-vol">22</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">785</span>–<span class="cit-lpage">794</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=22/5/785"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">26.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.26"
                             data-doi="10.1200/JCO.2005.05.1474">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gatzemeier</span>  <span class="cit-name-given-names">U</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pluzanska</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Szczesna</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva
                                    Lung Cancer Investigation Trial</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2007</span>;<span class="cit-vol">25</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">1545</span>–<span class="cit-lpage">1552</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=25/12/1545"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">27.</span><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference 27. in text"
                           id="ref-27">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.27">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Reck</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Von Pawel</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fischer</span>  <span class="cit-name-given-names">JR</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma
                                    (NSCLC): a randomized phase II study of the German Thoracic Oncology Working Group</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>(<span class="cit-supplement">15 suppl</span>):<span class="cit-fpage">7565</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Erlotinib%20versus%20carboplatin%2Fvinorelbine%20in%20elderly%20patients%20%28age%2070%20or%20older%29%20with%20advanced%20non-small%20cell%20lung%20carcinoma%20%28NSCLC%29%3A%20a%20randomized%20phase%20II%20study%20of%20the%20German%20Thoracic%20Oncology%20Working%20Group&amp;author=M%20Reck&amp;author=J%20Von%20Pawel&amp;author=JR%20Fischer&amp;publication_year=2010&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=7565">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">28.</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference 28. in text"
                           id="ref-28">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.28"
                             data-doi="10.1200/JCO.2009.24.3030">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Douillard</span>  <span class="cit-name-given-names">J-Y</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shepherd</span>  <span class="cit-name-given-names">FA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hirsh</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Molecular predictors of outcome with gefitinib and docetaxel in previously treated non–small-cell lung cancer: data from the
                                    randomized phase III INTEREST trial</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">744</span>–<span class="cit-lpage">752</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=28/5/744"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">29.</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference 29. in text"
                           id="ref-29">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.29"
                             data-doi="10.1016/S0140-6736(08)61758-4">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kim</span>  <span class="cit-name-given-names">ES</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hirsh</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mok</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial</span>.
                                 <abbr class="cit-jnl-abbrev">Lancet</abbr>.
                                 <span class="cit-pub-date">2008</span>;<span class="cit-vol">372</span>(<span class="cit-issue">9652</span>):<span class="cit-fpage">1809</span>–<span class="cit-lpage">1818</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(08)61758-4&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=19027483&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000261112000023&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gefitinib%20versus%20docetaxel%20in%20previously%20treated%20non-small-cell%20lung%20cancer%20%28INTEREST%29%3A%20a%20randomised%20phase%20III%20trial&amp;author=ES%20Kim&amp;author=V%20Hirsh&amp;author=T%20Mok&amp;publication_year=2008&amp;journal=Lancet&amp;volume=372&amp;issue=9652&amp;pages=1809-1818">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">30.</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference 30. in text"
                           id="ref-30">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.30">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zhang</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ma</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Song</span>  <span class="cit-name-given-names">X</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer
                                    (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial</span>.
                                 <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>.
                                 <span class="cit-pub-date">2011</span>;<span class="cit-vol">13</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">466</span>–<span class="cit-lpage">475</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gefitinib%20versus%20placebo%20as%20maintenance%20therapy%20in%20patients%20with%20locally%20advanced%20or%20metastatic%20non-small-cell%20lung%20cancer%20%28INFORM%3B%20C-TONG%200804%29%3A%20a%20multicentre%2C%20double-blind%20randomised%20phase%203%20trial&amp;author=L%20Zhang&amp;author=S%20Ma&amp;author=X%20Song&amp;publication_year=2011&amp;journal=Lancet%20Oncol&amp;volume=13&amp;issue=5&amp;pages=466-475">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">31.</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference 31. in text"
                           id="ref-31">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.31"
                             data-doi="10.1200/JCO.2007.15.0185">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Maruyama</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nishiwaki</span>  <span class="cit-name-given-names">Y</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tamura</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Phase III study, V-15–32, of gefitinib versus docetaxel in previously treated Japanese patients with non–small-cell lung cancer</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2008</span>;<span class="cit-vol">26</span>(<span class="cit-issue">26</span>):<span class="cit-fpage">4244</span>–<span class="cit-lpage">4252</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=26/26/4244"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">32.</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference 32. in text"
                           id="ref-32">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.32">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Perol</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chouaid</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Milleron</span>  <span class="cit-name-given-names">BJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine
                                    induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>(<span class="cit-supplement">15 suppl</span>):<span class="cit-fpage">7507</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Maintenance%20with%20either%20gemcitabine%20or%20erlotinib%20versus%20observation%20with%20predefined%20second-line%20treatment%20after%20cisplatin-gemcitabine%20induction%20chemotherapy%20in%20advanced%20NSCLC%3A%20IFCT-GFPC%200502%20phase%20III%20study&amp;author=M%20Perol&amp;author=C%20Chouaid&amp;author=BJ%20Milleron&amp;publication_year=2010&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=7507">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">33.</span><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference 33. in text"
                           id="ref-33">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.33">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mitsudomi</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Morita</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Yatabe</span>  <span class="cit-name-given-names">Y</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel
                                    (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth
                                    factor receptor (EGFR)</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-supplement">15 suppl</span>):<span class="cit-fpage">7521</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Updated%20overall%20survival%20results%20of%20WJTOG%203405%2C%20a%20randomized%20phase%20III%20trial%20comparing%20gefitinib%20%28G%29%20with%20cisplatin%20plus%20docetaxel%20%28CD%29%20as%20the%20first-line%20treatment%20for%20patients%20with%20non-small%20cell%20lung%20cancer%20harboring%20mutations%20of%20the%20epidermal%20growth%20factor%20receptor%20%28EGFR%29&amp;author=T%20Mitsudomi&amp;author=S%20Morita&amp;author=Y%20Yatabe&amp;publication_year=2012&amp;journal=J%20Clin%20Oncol&amp;volume=30&amp;pages=7521">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">34.</span><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference 34. in text"
                           id="ref-34">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.34">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Yang</span>  <span class="cit-name-given-names">JC-H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schuler</span>  <span class="cit-name-given-names">MH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Yamamoto</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment
                                    for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-supplement">15 suppl</span>):<span class="cit-fpage">LBA7500</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=LUX-Lung%203%3A%20a%20randomized%2C%20open-label%2C%20phase%20III%20study%20of%20afatinib%20versus%20pemetrexed%20and%20cisplatin%20as%20first-line%20treatment%20for%20patients%20with%20advanced%20adenocarcinoma%20of%20the%20lung%20harboring%20EGFR-activating%20mutations&amp;author=JC-H%20Yang&amp;author=MH%20Schuler&amp;author=N%20Yamamoto&amp;publication_year=2012&amp;journal=J%20Clin%20Oncol&amp;volume=30&amp;pages=LBA7500">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">35.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.35">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zhou</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wu</span>  <span class="cit-name-given-names">YL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Liu</span>  <span class="cit-name-given-names">X</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine
                                    (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-supplement">15 suppl</span>):<span class="cit-fpage">7520</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Overall%20survival%20%28OS%29%20results%20from%20OPTIMAL%20%28CTONG0802%29%2C%20a%20phase%20III%20trial%20of%20erlotinib%20%28E%29%20versus%20carboplatin%20plus%20gemcitabine%20%28GC%29%20as%20first-line%20treatment%20for%20Chinese%20patients%20with%20EGFR%20mutation-positive%20advanced%20non-small%20cell%20lung%20cancer%20%28NSCLC%29&amp;author=C%20Zhou&amp;author=YL%20Wu&amp;author=X%20Liu&amp;publication_year=2012&amp;journal=J%20Clin%20Oncol&amp;volume=30&amp;pages=7520">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">36.</span><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference 36. in text"
                           id="ref-36">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.36">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lee</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rudd</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Khan</span>  <span class="cit-name-given-names">I</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small
                                    cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>(<span class="cit-supplement">15 suppl</span>):<span class="cit-fpage">7504</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=TOPICAL%3A%20Randomized%20phase%20III%20trial%20of%20erlotinib%20compared%20with%20placebo%20in%20chemotherapy-naive%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%20and%20unsuitable%20for%20first-line%20chemotherapy&amp;author=S%20Lee&amp;author=R%20Rudd&amp;author=I%20Khan&amp;publication_year=2010&amp;journal=J%20Clin%20Oncol&amp;volume=28&amp;pages=7504">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">37.</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference 37. in text"
                           id="ref-37">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.37">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gatzemeier</span>  <span class="cit-name-given-names">U</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Heller</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Foernzler</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy
                                    +/– erlotinib (TALENT)</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>(<span class="cit-supplement">16 suppl</span>):<span class="cit-fpage">7028</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Exploratory%20analyses%20EGFR%2C%20kRAS%20mutations%20and%20other%20molecular%20markers%20in%20tumors%20of%20NSCLC%20patients%20%28pts%29%20treated%20with%20chemotherapy%20%2B%2F%E2%80%93%20erlotinib%20%28TALENT%29&amp;author=U%20Gatzemeier&amp;author=A%20Heller&amp;author=D%20Foernzler&amp;publication_year=2005&amp;journal=J%20Clin%20Oncol&amp;volume=23&amp;pages=7028">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">38.</span><a class="rev-xref-ref" href="#xref-ref-38-1" title="View reference 38. in text"
                           id="ref-38">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.38">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Inoue</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kobayashi</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Maemondo</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL)
                                    as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2011</span>;<span class="cit-vol">29</span>(<span class="cit-supplement">15 suppl</span>):<span class="cit-fpage">7519</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Final%20overall%20survival%20results%20of%20NEJ002%2C%20a%20phase%20III%20trial%20comparing%20gefitinib%20to%20carboplatin%20%28CBDCA%29%20plus%20paclitaxel%20%28TXL%29%20as%20the%20first-line%20treatment%20for%20advanced%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%20with%20EGFR%20mutations&amp;author=A%20Inoue&amp;author=K%20Kobayashi&amp;author=M%20Maemondo&amp;publication_year=2011&amp;journal=J%20Clin%20Oncol&amp;volume=29&amp;pages=7519">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">39.</span><a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference 39. in text"
                           id="ref-39">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.39"
                             data-doi="10.1200/JCO.2007.14.8924">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zhu</span>  <span class="cit-name-given-names">C-Q</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">da Cunha Santos</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ding</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group
                                    Study BR.21</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2008</span>;<span class="cit-vol">26</span>(<span class="cit-issue">26</span>):<span class="cit-fpage">4268</span>–<span class="cit-lpage">4675</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=26/26/4268"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">40.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.40"
                             data-doi="10.1056/NEJMoa050753">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shepherd</span>  <span class="cit-name-given-names">FA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rodrigues Pereira</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ciuleanu</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Erlotinib in previously treated non–small-cell lung cancer</span>.
                                 <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>.
                                 <span class="cit-pub-date">2005</span>;<span class="cit-vol">353</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">123</span>–<span class="cit-lpage">132</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa050753&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16014882&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000230438800004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Erlotinib%20in%20previously%20treated%20non%E2%80%93small-cell%20lung%20cancer&amp;author=FA%20Shepherd&amp;author=J%20Rodrigues%20Pereira&amp;author=T%20Ciuleanu&amp;publication_year=2005&amp;journal=N%20Engl%20J%20Med&amp;volume=353&amp;issue=2&amp;pages=123-132">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">41.</span><a class="rev-xref-ref" href="#xref-ref-41-1" title="View reference 41. in text"
                           id="ref-41">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.41"
                             data-doi="10.1016/S0140-6736(05)67625-8">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thatcher</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chang</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Parikh</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results
                                    from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)</span>.
                                 <abbr class="cit-jnl-abbrev">Lancet</abbr>.
                                 <span class="cit-pub-date">2005</span>;<span class="cit-vol">366</span>(<span class="cit-issue">9496</span>):<span class="cit-fpage">1527</span>–<span class="cit-lpage">1537</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(05)67625-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16257339&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000232984800021&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gefitinib%20plus%20best%20supportive%20care%20in%20previously%20treated%20patients%20with%20refractory%20advanced%20non-small-cell%20lung%20cancer%3A%20results%20from%20a%20randomised%2C%20placebo-controlled%2C%20multicentre%20study%20%28Iressa%20Survival%20Evaluation%20in%20Lung%20Cancer%29&amp;author=N%20Thatcher&amp;author=A%20Chang&amp;author=P%20Parikh&amp;publication_year=2005&amp;journal=Lancet&amp;volume=366&amp;issue=9496&amp;pages=1527-1537">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">42.</span><a class="rev-xref-ref" href="#xref-ref-42-1" title="View reference 42. in text"
                           id="ref-42">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.42">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sun</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lee</span>  <span class="cit-name-given-names">KH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kim</span>  <span class="cit-name-given-names">SW</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based
                                    chemotherapy (KCSG-LU08-01)</span> [published online ahead of print June 6, 2012]. <abbr class="cit-jnl-abbrev">Cancer</abbr>.
                                 <span class="cit-pub-date">2012</span>. doi:<span class="cit-comment">10.1002/cncr.27630</span>.
                                 </cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gefitinib%20versus%20pemetrexed%20as%20second-line%20treatment%20in%20patients%20with%20nonsmall%20cell%20lung%20cancer%20previously%20treated%20with%20platinum-based%20chemotherapy%20%28KCSG-LU08-01%29&amp;author=JM%20Sun&amp;author=KH%20Lee&amp;author=SW%20Kim&amp;publication_year=2012&amp;journal=Cancer">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">43.</span><a class="rev-xref-ref" href="#xref-ref-43-1" title="View reference 43. in text"
                           id="ref-43">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.43"
                             data-doi="10.1016/S1470-2045(12)70412-6">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lee</span>  <span class="cit-name-given-names">SM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Khan</span>  <span class="cit-name-given-names">I</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Upadhyay</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind,
                                    placebo-controlled, phase 3 trial</span>.
                                 <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">13</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1161</span>–<span class="cit-lpage">1170</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(12)70412-6&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=23078958&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000310570900047&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=First-line%20erlotinib%20in%20patients%20with%20advanced%20non-small-cell%20lung%20cancer%20unsuitable%20for%20chemotherapy%20%28TOPICAL%29%3A%20a%20double-blind%2C%20placebo-controlled%2C%20phase%203%20trial&amp;author=SM%20Lee&amp;author=I%20Khan&amp;author=S%20Upadhyay&amp;publication_year=2012&amp;journal=Lancet%20Oncol&amp;volume=13&amp;issue=11&amp;pages=1161-1170">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">44.</span><a class="rev-xref-ref" href="#xref-ref-44-1" title="View reference 44. in text"
                           id="ref-44">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.44"
                             data-doi="10.1200/JCO.2011.39.9782">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pérol</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chouaid</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pérol</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line
                                    treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non–small-cell lung cancer</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-issue">28</span>):<span class="cit-fpage">3516</span>–<span class="cit-lpage">3524</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=30/28/3516"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">45.</span><a class="rev-xref-ref" href="#xref-ref-45-1" title="View reference 45. in text"
                           id="ref-45">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.45"
                             data-doi="10.1200/JCO.2005.02.7078">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bell</span>  <span class="cit-name-given-names">DW</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lynch</span>  <span class="cit-name-given-names">TJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Haserlat</span>  <span class="cit-name-given-names">SM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: molecular analysis of the
                                    IDEAL/INTACT gefitinib trials</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>(<span class="cit-issue">31</span>):<span class="cit-fpage">8081</span>–<span class="cit-lpage">8092</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/31/8081"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">46.</span><a class="rev-xref-ref" href="#xref-ref-46-1" title="View reference 46. in text"
                           id="ref-46">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.46"
                             data-doi="10.1371/journal.pone.0026646">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hotta</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kiura</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fujiwara</span>  <span class="cit-name-given-names">Y</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic
                                    review</span>.
                                 <abbr class="cit-jnl-abbrev">PLoS One</abbr>.
                                 <span class="cit-pub-date">2011</span>;<span class="cit-vol">6</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">e26646</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1371/journal.pone.0026646&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22114662&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Role%20of%20survival%20post-progression%20in%20phase%20III%20trials%20of%20systemic%20chemotherapy%20in%20advanced%20non-small-cell%20lung%20cancer%3A%20a%20systematic%20review&amp;author=K%20Hotta&amp;author=K%20Kiura&amp;author=Y%20Fujiwara&amp;publication_year=2011&amp;journal=PLoS%20One&amp;volume=6&amp;issue=11&amp;pages=e26646">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">47.</span><a class="rev-xref-ref" href="#xref-ref-47-1" title="View reference 47. in text"
                           id="ref-47">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.47"
                             data-doi="10.1002/sim.2641">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fleming</span>  <span class="cit-name-given-names">TR</span></span></li>
                              </ol><cite>.
                                 <span class="cit-article-title">Standard versus adaptive monitoring procedures: a commentary</span>.
                                 <abbr class="cit-jnl-abbrev">Stat Med</abbr>.
                                 <span class="cit-pub-date">2006</span>;<span class="cit-vol">25</span>(<span class="cit-issue">19</span>):<span class="cit-fpage">3305</span>–<span class="cit-lpage">3312</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.2641&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16850447&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000240880300009&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Standard%20versus%20adaptive%20monitoring%20procedures%3A%20a%20commentary&amp;author=TR%20Fleming&amp;publication_year=2006&amp;journal=Stat%20Med&amp;volume=25&amp;issue=19&amp;pages=3305-3312">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">48.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.48"
                             data-doi="10.1200/JCO.2008.20.4107">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fleming</span>  <span class="cit-name-given-names">TR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rothmann</span>  <span class="cit-name-given-names">MD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lu</span>  <span class="cit-name-given-names">HL</span></span></li>
                              </ol><cite>.
                                 <span class="cit-article-title">Issues in using progression-free survival when evaluating oncology products</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2009</span>;<span class="cit-vol">27</span>(<span class="cit-issue">17</span>):<span class="cit-fpage">2874</span>–<span class="cit-lpage">2880</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=27/17/2874"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">49.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.49"
                             data-doi="10.1200/JCO.2008.16.1711">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dodd</span>  <span class="cit-name-given-names">LE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Korn</span>  <span class="cit-name-given-names">EL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Freidlin</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Blinded independent central review of progression-free survival in phase III clinical trials: important design element or
                                    unnecessary expense?</span>
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2008</span>;<span class="cit-vol">26</span>(<span class="cit-issue">22</span>):<span class="cit-fpage">3791</span>–<span class="cit-lpage">3796</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=26/22/3791"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">50.</span><a class="rev-xref-ref" href="#xref-ref-50-1" title="View reference 50. in text"
                           id="ref-50">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.50">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ciardiello</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Caputo</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bianco</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth
                                    factor receptor-selective tyrosine kinase inhibitor</span>.
                                 <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr>.
                                 <span class="cit-pub-date">2000</span>;<span class="cit-vol">6</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">2053</span>–<span class="cit-lpage">2063</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=6/5/2053"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">51.</span><a class="rev-xref-ref" href="#xref-ref-51-1" title="View reference 51. in text"
                           id="ref-51">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.51">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sirotnak</span>  <span class="cit-name-given-names">FM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zakowski</span>  <span class="cit-name-given-names">MF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Miller</span>  <span class="cit-name-given-names">VA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Scher</span>  <span class="cit-name-given-names">HI</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kris</span>  <span class="cit-name-given-names">MG</span></span></li>
                              </ol><cite>.
                                 <span class="cit-article-title">Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an
                                    inhibitor of EGFR tyrosine kinase</span>.
                                 <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr>.
                                 <span class="cit-pub-date">2000</span>;<span class="cit-vol">6</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">4885</span>–<span class="cit-lpage">4892</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=6/12/4885"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">52.</span><a class="rev-xref-ref" href="#xref-ref-52-1" title="View reference 52. in text"
                           id="ref-52">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.52"
                             data-doi="10.1200/JCO.2011.40.1315">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jänne</span>  <span class="cit-name-given-names">PA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wang</span>  <span class="cit-name-given-names">X</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Socinski</span>  <span class="cit-name-given-names">MA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former
                                    smokers with advanced lung adenocarcinoma: CALGB 30406 trial</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-issue">17</span>):<span class="cit-fpage">2063</span>–<span class="cit-lpage">2069</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=30/17/2063"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">53.</span><a class="rev-xref-ref" href="#xref-ref-53-1" title="View reference 53. in text"
                           id="ref-53">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.53"
                             data-doi="10.1016/S1470-2045(12)70001-3">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Luis</span>  <span class="cit-name-given-names">P-A</span></span></li>
                              </ol><cite>.
                                 <span class="cit-article-title">Beyond first-line NSCLC therapy: chemotherapy or erlotinib?</span>
                                 <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">13</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">225</span>–<span class="cit-lpage">227</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(12)70001-3&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22277836&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000300880600022&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Beyond%20first-line%20NSCLC%20therapy%3A%20chemotherapy%20or%20erlotinib%3F&amp;author=P-A%20Luis&amp;publication_year=2012&amp;journal=Lancet%20Oncol&amp;volume=13&amp;issue=3&amp;pages=225-227">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">54.</span><a class="rev-xref-ref" href="#xref-ref-54-1" title="View reference 54. in text"
                           id="ref-54">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.54"
                             data-doi="10.2353/jmoldx.2010.090188">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tsiatis</span>  <span class="cit-name-given-names">AC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Norris-Kirby</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rich</span>  <span class="cit-name-given-names">RG</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic
                                    and clinical implications</span>.
                                 <abbr class="cit-jnl-abbrev">J Mol Diagn</abbr>.
                                 <span class="cit-pub-date">2010</span>;<span class="cit-vol">12</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">425</span>–<span class="cit-lpage">432</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2353/jmoldx.2010.090188&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20431034&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000279800900006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Comparison%20of%20Sanger%20sequencing%2C%20pyrosequencing%2C%20and%20melting%20curve%20analysis%20for%20the%20detection%20of%20KRAS%20mutations%3A%20diagnostic%20and%20clinical%20implications&amp;author=AC%20Tsiatis&amp;author=A%20Norris-Kirby&amp;author=RG%20Rich&amp;publication_year=2010&amp;journal=J%20Mol%20Diagn&amp;volume=12&amp;issue=4&amp;pages=425-432">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">55.</span><a class="rev-xref-ref" href="#xref-ref-55-1" title="View reference 55. in text"
                           id="ref-55">↵</a>
                        
                        
                        <div class="cit ref-cit ref-journal" id="cit-105.9.595.55"
                             data-doi="10.1056/NEJMoa0800668">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Maheswaran</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sequist</span>  <span class="cit-name-given-names">LV</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nagrath</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Detection of mutations in EGFR in circulating lung-cancer cells</span>.
                                 <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>.
                                 <span class="cit-pub-date">2008</span>;<span class="cit-vol">359</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">366</span>–<span class="cit-lpage">377</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa0800668&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=18596266&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000257852100005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Detection%20of%20mutations%20in%20EGFR%20in%20circulating%20lung-cancer%20cells&amp;author=S%20Maheswaran&amp;author=LV%20Sequist&amp;author=S%20Nagrath&amp;publication_year=2008&amp;journal=N%20Engl%20J%20Med&amp;volume=359&amp;issue=4&amp;pages=366-377">Google Scholar</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">56.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.56"
                             data-doi="10.1158/1078-0432.CCR-10-2158">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rosell</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Molina</span>  <span class="cit-name-given-names">MA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Costa</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients
                                    with EGFR mutations</span>.
                                 <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr>.
                                 <span class="cit-pub-date">2011</span>;<span class="cit-vol">17</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">1160</span>–<span class="cit-lpage">1168</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=17/5/1160"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">57.</span>
                        
                        
                        <div class="cit ref-cit ref-journal no-rev-xref" id="cit-105.9.595.57"
                             data-doi="10.1200/JCO.2011.38.3224">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Su</span>  <span class="cit-name-given-names">K-Y</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chen</span>  <span class="cit-name-given-names">H-Y</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Li</span>  <span class="cit-name-given-names">K-C</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al.</span></li>
                              </ol><cite>
                                 <span class="cit-article-title">Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter egfr tyrosine kinase inhibitor response
                                    duration in patients with non–small-cell lung cancer</span>.
                                 <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>.
                                 <span class="cit-pub-date">2012</span>;<span class="cit-vol">30</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">433</span>–<span class="cit-lpage">440</span>.
                                 </cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=30/4/433"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div>
            <div id="related">
               <h2>Related articles</h2>
               <ul class="related-list">
                  <div class="cit has-earlier-version">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">Solicited Editorial<span class="cit-sep cit-sep-after-article-section">:</span> </span><ul class="cit-auth-list">
                           <li class="first-item"><span class="cit-auth cit-auth-type-author">Stephanie Cardarella</span><span class="cit-sep cit-sep-two-item-separator"> and</span></li>
                           <li class="last-item"><span class="cit-auth cit-auth-type-author">Bruce E. Johnson</span></li>  
                        </ul><span class="cit-title">Meta-Analysis of EGFR Kinase Inhibitors: Not Always Greater Than the Sum of Its Parts </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2013<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">105 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>9<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">589</span><span class="cit-sep">-</span><span class="cit-last-page">590</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/djt085 </span><span class="cit-ahead-of-print-date"><span class="cit-sep cit-sep-before-article-ahead-of-print-date">first published online </span>April 17, 2013 </span><span class="cit-page-count"><span class="cit-sep cit-sep-before-article-page-count">(</span>2<span class="cit-sep cit-sep-after-article-page-count"> pages)</span> </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;105/9/589 pdf_extract,full,reprint"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/105/9/589.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/105/9/589.full" rel="full-text">Full Text (HTML)</a></li>
                           <li class="last-item"><a href="/content/105/9/589.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                        </ul>  
                     </div> 
                  </div>
               </ul>
            </div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/105/9/593.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/105/9/606.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/105/9.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2013) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    105
                                    </span><span class="slug-issue">
                                    (9):
                                    </span><span class="slug-pages">
                                    595-605.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djt072" class="slug-doi">10.1093/jnci/djt072</span>
                                    </span>
                                 </cite>
                              
                              
                              <span class="slug-metadata-note ahead-of-print">
                                 
                                 First published online
                                 
                                 <span class="slug-ahead-of-print-date">April 17, 2013</span>
                                 </span>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/105/9/595.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/105/9/595.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                        <li><a href="/content/105/9/595/suppl/DC1" rel="supplemental-data"
                              class="dslink-supplementary-data">Supplementary Data</a></li>
                        <li class="cb-versions">
                           <div><span id="pap-all-versions-label">All Versions of this Article:</span><ol class="version-list">
                                 <li><a href="/content/early/2013/04/17/jnci.djt072">djt072v1</a></li>
                                 <li class="current-li"><span>105/9/595</span> <span class="current-version">most recent</span></li>
                              </ol>
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=Review&amp;sortspec=date&amp;submit=Submit">Review</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;105/9/595" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B105%2F9%2F595&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/105/9/595.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=105/9/595&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/105/9/595.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3Bdjt072&amp;citation=Lee%20et%20al.%20105%20%289%29:%20595&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B105%2F9%2F595&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=23594426&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B105%2F9%2F595">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B105%2F9%2F595">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Impact%20of%20EGFR%20Inhibitor%20in%20Non%E2%80%93Small%20Cell%20Lung%20Cancer%20on%20Progression-Free%20and%20Overall%20Survival%3A%20A%20Meta-Analysis%3A%20&amp;publicationDate=05%2F01%2F2013&amp;author=Chee%20Khoon%20Lee%2C%20Chris%20Brown%2C%20Richard%20J.%20Gralla%2C%20Vera%20Hirsh%2C%20Sumitra%20Thongprasert%2C%20Chun-Ming%20Tsai%2C%20Eng%20Huat%20Tan%2C%20James%20Chung-Man%20Ho%2C%20Da%20Tong%20Chu%2C%20Adel%20Zaatar%2C%20Jemela%20Anne%20Osorio%20Sanchez%2C%20Vu%20Van%20Vu%2C%20Joseph%20Siu%20Kie%20Au%2C%20Akira%20Inoue%2C%20Siow%20Ming%20Lee%2C%20Val%20Gebski%2C%20James%20Chih-Hsin%20Yang&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjt072&amp;volumeNum=105&amp;issueNum=9&amp;startPage=595&amp;endPage=605&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/105/9/595.full?cited-by=yes&amp;legid=jnci;105/9/595#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/105/9/595" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/105/9/595?access_num=/jnci/105/9/595"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F105%2F9%2F595&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/105/9/595.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ALee%20author%3AC.K.%22"
                              class="cb-art-gs-auth author-link">Articles by  Lee, C. K.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AYang%20author%3AJ.C.H.%22"
                              class="cb-art-gs-auth author-link">Articles by  Yang, J. C. H.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/105/9/595.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=23594426&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Lee%20CK&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Lee, C. K.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Brown%20C&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Brown, C.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Gralla%20RJ&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Gralla, R. J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Hirsh%20V&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Hirsh, V.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Thongprasert%20S&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Thongprasert, S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Tsai%20CM&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Tsai, C. M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Tan%20EH&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Tan, E. H.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Ho%20JC&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Ho, J. C. M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Chu%20DT&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Chu, D. T.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Zaatar%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Zaatar, A.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Osorio%20Sanchez%20JA&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Osorio Sanchez, J. A.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Vu%20VV&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Vu, V. V.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Au%20JS&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Au, J. S. K.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Inoue%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Inoue, A.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Lee%20SM&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Lee, S. M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Gebski%20V&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Gebski, V.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Yang%20JC&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Yang, J. C. H.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="#related">Related articles in this journal</a></li>
                        <li><a href="/content/105/9/595.full?related-urls=yes&amp;legid=jnci;105/9/595#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B105%2F9%2F595&amp;current-view-path=/content/105/9/595.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/105/9/595&amp;title=Impact%20of%20EGFR%20Inhibitor%20in%20Non%E2%80%93Small%20Cell%20Lung%20Cancer%20on%20Progression-Free%20and%20Overall%20Survival%3A%20A%20Meta-Analysis+--+Lee%20et%20al.%20105%20%289%29%3A%20595+--+jnci.j&amp;doi=10.1093/jnci/djt072&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/105/9/595&amp;title=Impact%20of%20EGFR%20Inhibitor%20in%20Non%E2%80%93Small%20Cell%20Lung%20Cancer%20on%20Progression-Free%20and%20Overall%20Survival%3A%20A%20Meta-Analysis+--+Lee%20et%20al.%20105%20%289%29%3A%20595+--+jnci.j&amp;doi=10.1093/jnci/djt072&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/105/9/595&amp;title=Impact%20of%20EGFR%20Inhibitor%20in%20Non%E2%80%93Small%20Cell%20Lung%20Cancer%20on%20Progression-Free%20and%20Overall%20Survival%3A%20A%20Meta-Analysis+--+Lee%20et%20al.%20105%20%289%29%3A%20595+--+jnci.j&amp;doi=10.1093/jnci/djt072&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/105/9/595&amp;title=Impact%20of%20EGFR%20Inhibitor%20in%20Non%E2%80%93Small%20Cell%20Lung%20Cancer%20on%20Progression-Free%20and%20Overall%20Survival%3A%20A%20Meta-Analysis+--+Lee%20et%20al.%20105%20%289%29%3A%20595+--+jnci.j&amp;doi=10.1093/jnci/djt072&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/105/9/595&amp;title=Impact%20of%20EGFR%20Inhibitor%20in%20Non%E2%80%93Small%20Cell%20Lung%20Cancer%20on%20Progression-Free%20and%20Overall%20Survival%3A%20A%20Meta-Analysis+--+Lee%20et%20al.%20105%20%289%29%3A%20595+--+jnci.j&amp;doi=10.1093/jnci/djt072&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/105/9/595&amp;title=Impact%20of%20EGFR%20Inhibitor%20in%20Non%E2%80%93Small%20Cell%20Lung%20Cancer%20on%20Progression-Free%20and%20Overall%20Survival%3A%20A%20Meta-Analysis+--+Lee%20et%20al.%20105%20%289%29%3A%20595+--+jnci.j&amp;doi=10.1093/jnci/djt072&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-5">Methods</a></li>
                        <li><a href="#sec-9">Results</a></li>
                        <li><a href="#sec-15">Discussion</a></li>
                        <li><a href="#sec-16">Funding</a></li>
                        <li><a href="#notes-1">Notes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/105/9/595.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/105/9/595.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>